Breast Cancer
Balixafortide in combination with eribulin did not improve objective response rate compared to eribulin alone for the treatment of HER2-negative, locally recurrent or metastatic breast cancer, missing the coprimary end point of the FORTRESS study.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5